Clinical Trials

Inclusion Criteria:

1. Patients ≥18 years of age.

2. Patients must have a histologic diagnosis of GIST.

3. Patients must have GIST that has progressed on or have intolerance to at least 2 lines
of prior TKI therapies.

4. Patients must have an Eastern Cooperative Oncology Group performance score of ≤ 2.

5. If a female of childbearing potential, must have a negative pregnancy test prior to
enrollment and agree to follow the contraception requirements.

6. Adequate organ and bone marrow function.

Exclusion Criteria:

1. Received prior anticancer or other investigational therapy within 28 days or 5× the
half-life prior to the first dose.

2. Prior treatment with ripretinib.

3. Patients who have had prior repaglinide treatment within 30 days of screening.

4. History or presence of clinically relevant cardiovascular abnormalities.

5. Gastrointestinal abnormalities including but not limited to:

- inability to take oral medication,

- malabsorption syndromes,

- requirement for intravenous alimentation.

6. Patients who have type 1 or type 2 diabetes.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 9/29/22. Questions regarding updates should be directed to the study team contact.